The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications.
Identifieur interne : 000402 ( Main/Exploration ); précédent : 000401; suivant : 000403The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications.
Auteurs : Leen Mathys [Belgique] ; Jan Balzarini [Belgique]Source :
- Expert opinion on therapeutic targets [ 1744-7631 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Antioxydants (métabolisme), Antiviraux (pharmacologie), Humains (MeSH), Maladies virales (traitement médicamenteux), Maladies virales (virologie), Oxidoreductases (antagonistes et inhibiteurs), Oxidoreductases (métabolisme), Protéines de l'enveloppe virale (métabolisme), Pénétration virale (MeSH), Récepteurs de surface cellulaire (métabolisme), Stress oxydatif (MeSH), Thérapie moléculaire ciblée (MeSH), Évolution de la maladie (MeSH).
- MESH :
- antagonistes et inhibiteurs : Oxidoreductases.
- métabolisme : Antioxydants, Oxidoreductases, Protéines de l'enveloppe virale, Récepteurs de surface cellulaire.
- pharmacologie : Antiviraux.
- traitement médicamenteux : Maladies virales.
- virologie : Maladies virales.
- Animaux, Humains, Pénétration virale, Stress oxydatif, Thérapie moléculaire ciblée, Évolution de la maladie.
English descriptors
- KwdEn :
- Animals (MeSH), Antioxidants (metabolism), Antiviral Agents (pharmacology), Disease Progression (MeSH), Humans (MeSH), Molecular Targeted Therapy (MeSH), Oxidative Stress (MeSH), Oxidoreductases (antagonists & inhibitors), Oxidoreductases (metabolism), Receptors, Cell Surface (metabolism), Viral Envelope Proteins (metabolism), Virus Diseases (drug therapy), Virus Diseases (virology), Virus Internalization (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Oxidoreductases.
- chemical , metabolism : Antioxidants, Oxidoreductases, Receptors, Cell Surface, Viral Envelope Proteins.
- chemical , pharmacology : Antiviral Agents.
- drug therapy : Virus Diseases.
- virology : Virus Diseases.
- Animals, Disease Progression, Humans, Molecular Targeted Therapy, Oxidative Stress, Virus Internalization.
Abstract
INTRODUCTION
Cellular oxidoreductases catalyze thiol/disulfide exchange reactions in susceptible proteins and contribute to the cellular defense against oxidative stress. Oxidoreductases and oxidative stress are also involved in viral infections. In this overview, different aspects of the role of cellular oxidoreductases and oxidative stress during viral infections are discussed from a chemotherapeutic viewpoint.
AREAS COVERED
Entry of enveloped viruses into their target cells is triggered by the interaction of viral envelope glycoproteins with cellular (co)receptor(s) and depends on obligatory conformational changes in these viral envelope glycoproteins and/or cellular receptors. For some viruses, these conformational changes are mediated by cell surface-associated cellular oxidoreductases, which mediate disulfide bridge reductions in viral envelope glycoprotein(s). Therefore, targeting these oxidoreductases using oxidoreductase inhibitors might yield an interesting strategy to block viral entry of these viruses. Furthermore, since viral infections are often associated with systemic oxidative stress, contributing to disease progression, the enhancement of the cellular antioxidant defense systems might have potential as an adjuvant antiviral strategy, slowing down disease progression.
EXPERT OPINION
Promising antiviral data were obtained for both strategies. However, potential pitfalls have also been identified for these strategies, indicating that it is important to carefully assess the benefits versus risks of these antiviral strategies.
DOI: 10.1517/14728222.2015.1068760
PubMed: 26178644
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications.</title><author><name sortKey="Mathys, Leen" sort="Mathys, Leen" uniqKey="Mathys L" first="Leen" last="Mathys">Leen Mathys</name><affiliation wicri:level="1"><nlm:affiliation>a 1 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a 1 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name><affiliation wicri:level="1"><nlm:affiliation>b 2 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven, Belgium +32 16 3 37352 ; +32 16 3 37340 ; jan.balzarini@rega.kuleuven.be.</nlm:affiliation><country wicri:rule="url">Belgique</country><wicri:regionArea>b 2 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26178644</idno><idno type="pmid">26178644</idno><idno type="doi">10.1517/14728222.2015.1068760</idno><idno type="wicri:Area/Main/Corpus">000515</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000515</idno><idno type="wicri:Area/Main/Curation">000515</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000515</idno><idno type="wicri:Area/Main/Exploration">000515</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications.</title><author><name sortKey="Mathys, Leen" sort="Mathys, Leen" uniqKey="Mathys L" first="Leen" last="Mathys">Leen Mathys</name><affiliation wicri:level="1"><nlm:affiliation>a 1 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>a 1 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name><affiliation wicri:level="1"><nlm:affiliation>b 2 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven, Belgium +32 16 3 37352 ; +32 16 3 37340 ; jan.balzarini@rega.kuleuven.be.</nlm:affiliation><country wicri:rule="url">Belgique</country><wicri:regionArea>b 2 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author></analytic><series><title level="j">Expert opinion on therapeutic targets</title><idno type="eISSN">1744-7631</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antioxidants (metabolism)</term><term>Antiviral Agents (pharmacology)</term><term>Disease Progression (MeSH)</term><term>Humans (MeSH)</term><term>Molecular Targeted Therapy (MeSH)</term><term>Oxidative Stress (MeSH)</term><term>Oxidoreductases (antagonists & inhibitors)</term><term>Oxidoreductases (metabolism)</term><term>Receptors, Cell Surface (metabolism)</term><term>Viral Envelope Proteins (metabolism)</term><term>Virus Diseases (drug therapy)</term><term>Virus Diseases (virology)</term><term>Virus Internalization (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antioxydants (métabolisme)</term><term>Antiviraux (pharmacologie)</term><term>Humains (MeSH)</term><term>Maladies virales (traitement médicamenteux)</term><term>Maladies virales (virologie)</term><term>Oxidoreductases (antagonistes et inhibiteurs)</term><term>Oxidoreductases (métabolisme)</term><term>Protéines de l'enveloppe virale (métabolisme)</term><term>Pénétration virale (MeSH)</term><term>Récepteurs de surface cellulaire (métabolisme)</term><term>Stress oxydatif (MeSH)</term><term>Thérapie moléculaire ciblée (MeSH)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Oxidoreductases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antioxidants</term><term>Oxidoreductases</term><term>Receptors, Cell Surface</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Oxidoreductases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antioxydants</term><term>Oxidoreductases</term><term>Protéines de l'enveloppe virale</term><term>Récepteurs de surface cellulaire</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Progression</term><term>Humans</term><term>Molecular Targeted Therapy</term><term>Oxidative Stress</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Pénétration virale</term><term>Stress oxydatif</term><term>Thérapie moléculaire ciblée</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>Cellular oxidoreductases catalyze thiol/disulfide exchange reactions in susceptible proteins and contribute to the cellular defense against oxidative stress. Oxidoreductases and oxidative stress are also involved in viral infections. In this overview, different aspects of the role of cellular oxidoreductases and oxidative stress during viral infections are discussed from a chemotherapeutic viewpoint.</p></div><div type="abstract" xml:lang="en"><p><b>AREAS COVERED</b></p><p>Entry of enveloped viruses into their target cells is triggered by the interaction of viral envelope glycoproteins with cellular (co)receptor(s) and depends on obligatory conformational changes in these viral envelope glycoproteins and/or cellular receptors. For some viruses, these conformational changes are mediated by cell surface-associated cellular oxidoreductases, which mediate disulfide bridge reductions in viral envelope glycoprotein(s). Therefore, targeting these oxidoreductases using oxidoreductase inhibitors might yield an interesting strategy to block viral entry of these viruses. Furthermore, since viral infections are often associated with systemic oxidative stress, contributing to disease progression, the enhancement of the cellular antioxidant defense systems might have potential as an adjuvant antiviral strategy, slowing down disease progression.</p></div><div type="abstract" xml:lang="en"><p><b>EXPERT OPINION</b></p><p>Promising antiviral data were obtained for both strategies. However, potential pitfalls have also been identified for these strategies, indicating that it is important to carefully assess the benefits versus risks of these antiviral strategies.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26178644</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7631</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Expert opinion on therapeutic targets</Title><ISOAbbreviation>Expert Opin Ther Targets</ISOAbbreviation></Journal><ArticleTitle>The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications.</ArticleTitle><Pagination><MedlinePgn>123-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14728222.2015.1068760</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cellular oxidoreductases catalyze thiol/disulfide exchange reactions in susceptible proteins and contribute to the cellular defense against oxidative stress. Oxidoreductases and oxidative stress are also involved in viral infections. In this overview, different aspects of the role of cellular oxidoreductases and oxidative stress during viral infections are discussed from a chemotherapeutic viewpoint.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">Entry of enveloped viruses into their target cells is triggered by the interaction of viral envelope glycoproteins with cellular (co)receptor(s) and depends on obligatory conformational changes in these viral envelope glycoproteins and/or cellular receptors. For some viruses, these conformational changes are mediated by cell surface-associated cellular oxidoreductases, which mediate disulfide bridge reductions in viral envelope glycoprotein(s). Therefore, targeting these oxidoreductases using oxidoreductase inhibitors might yield an interesting strategy to block viral entry of these viruses. Furthermore, since viral infections are often associated with systemic oxidative stress, contributing to disease progression, the enhancement of the cellular antioxidant defense systems might have potential as an adjuvant antiviral strategy, slowing down disease progression.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Promising antiviral data were obtained for both strategies. However, potential pitfalls have also been identified for these strategies, indicating that it is important to carefully assess the benefits versus risks of these antiviral strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathys</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>a 1 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balzarini</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>b 2 Rega Institute for Medical Research, KU Leuven , Minderbroedersstraat 10 blok x - bus 1030, Leuven, Belgium +32 16 3 37352 ; +32 16 3 37340 ; jan.balzarini@rega.kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Ther Targets</MedlineTA><NlmUniqueID>101127833</NlmUniqueID><ISSNLinking>1472-8222</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.-</RegistryNumber><NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral chemotherapy</Keyword><Keyword MajorTopicYN="N">glutaredoxin</Keyword><Keyword MajorTopicYN="N">nutritional antioxidants</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">oxidoreductases</Keyword><Keyword MajorTopicYN="N">oxidoreduction</Keyword><Keyword MajorTopicYN="N">protein disulfide isomerase</Keyword><Keyword MajorTopicYN="N">thioredoxin</Keyword><Keyword MajorTopicYN="N">viral entry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26178644</ArticleId><ArticleId IdType="doi">10.1517/14728222.2015.1068760</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li></country></list><tree><country name="Belgique"><noRegion><name sortKey="Mathys, Leen" sort="Mathys, Leen" uniqKey="Mathys L" first="Leen" last="Mathys">Leen Mathys</name></noRegion><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/GlutaredoxinV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000402 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000402 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= GlutaredoxinV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26178644
|texte= The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26178644" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GlutaredoxinV1
| This area was generated with Dilib version V0.6.37. |  |